Ocular abnormalities in mice lacking the Ski proto-oncogene

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 10, 2006, Pages 4231-4237

  McGannon, Peter ^a   Miyazaki, Yasumasa ^a   Gupta, Pankaj C ^a   Traboulsi, Elias I ^a   Colmenares, Clemencia ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; CELL MARKER; RETINOIC ACID; RETINOIC ACID RECEPTOR; TRANSCRIPTION FACTOR PAX6; VASCULOTROPIN RECEPTOR 2; BETA III TUBULIN PROTEIN, MOUSE; BETA III-TUBULIN PROTEIN, MOUSE; DNA BINDING PROTEIN; EYE PROTEIN; HOMEODOMAIN PROTEIN; ONCOPROTEIN; PAIRED BOX TRANSCRIPTION FACTOR; REPRESSOR PROTEIN; SKI PROTEIN, MOUSE; TUBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE SEGMENT; ARTICLE; C57BL 6 MOUSE; CELL STRUCTURE; COLOBOMA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; EYE DEVELOPMENT; EYE DISEASE; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC CORRELATION; GENETIC DISORDER; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MICROPHTHALMIA; MOUSE; NONHUMAN; PERSISTENT HYPERPLASTIC PRIMARY VITREOUS; PETERS ANOMALY; PHENOTYPE; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; RECEPTOR GENE; RETINA FOLD; RETINA MALFORMATION; RETROLENTAL FIBROPLASIA; SIGNAL TRANSDUCTION; SKI GENE; TRANSCRIPTION INITIATION; VASCULAR TISSUE; VITREOUS BODY; ANIMAL; C57BL MOUSE; CONGENITAL MALFORMATION; DISEASE MODEL; EYE MALFORMATION; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; HYPERPLASIA; IN SITU HYBRIDIZATION; METABOLISM; MOUSE MUTANT; MULTIPLE MALFORMATION SYNDROME; PATHOLOGY; PHYSIOLOGY;

ABNORMALITIES, MULTIPLE; ANIMALS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; EYE ABNORMALITIES; EYE PROTEINS; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENOTYPE; HOMEODOMAIN PROTEINS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROPHTHALMOS; PAIRED BOX TRANSCRIPTION FACTORS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; TUBULIN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VITREOUS BODY;

EID: 33750580121     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-1543     Document Type: Article

References (53)

1. Lang RA, Bishop JM. Macrophages are required for cell death and tissue remodeling in the developing mouse eye. Cell. 1993;74:453-462.
2. Lang R, Lustig M, Francois F, Sellinger M, Plesken H. Apoptosis during macrophage-dependent ocular tissue remodelling. Development. 1994;120:3395-3403.
3. Goldberg MF. Persistent fetal vasculature (PFV): an integrated interpretation of signs and symptoms associated with persistent hyperplastic primary vitreous (PHPV). LIV Edward Jackson Memorial Lecture. Am J Ophthalmol. 1997;124:587-626.
4. Reese AB. Persistent hyperplastic primary vitreous. Am J Ophthalmol 1955;40:317-331.
5. Ozeki H, Shirai S. Developmental eye abnormalities in mouse fetuses induced by retinoic acid. Jpn J Ophthalmol. 1998;42:162-167.
6. Ozeki H, Shirai S, Ikeda K, Ogura Y. Critical period for retinoic acid-induced developmental abnormalities of the vitreous in mouse fetuses. Exp Eye Res. 1999;68:223-228.
7. Lohnes D, Mark M, Mendelsohn C, et al. Function of the retinoic acid receptors (RARs) during development: I Craniofacial and skeletal abnormalities in RAR double mutants. Development. 1994;120:2723-2748.
8. Grondona JM, Kastner P, Gansmuller A, Decimo D, Chambon P, Mark M. Retinal dysplasia and degeneration in RARbeta2/RARgamma2 compound mutant mice. Development 1996;122:2173-2188.
9. Ikeda S, Hawes NL, Chang B, Avery CS, Smith RS, Nishina PM. Severe ocular abnormalities in C57BL/6 but not in 129/Sv p53-deficient mice. Invest Ophthalmol Vis Sci 1999;40:1874-1878.
10. Reichel MB, Ali RR, D'Esposito F, et al. High frequency of persistent hyperplastic primary vitreous and cataracts in p53-deficient mice. Cell Death Differ 1998;5:156-162.
11. Martin AC, Thornton JD, Liu J, et al. Pathogenesis of persistent hyperplastic primary vitreous in mice lacking the arf tumor suppressor gene. Invest Ophthalmol Vis Sci 2004;45:3387-3396.
12. McKeller RN, Fowler JL, Cunningham JJ, et al. The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proc Natl Acad Sci USA. 2002;99:3848-3853.
13. Paradis H, Liu CY, Saika S, et al. Tubedown-1 in remodeling of the developing vitreal vasculature in vivo and regulation of capillary outgrowth in vitro. Dev Biol 2002;249:140-155.
14. Saika S, Saika S, Liu CY, et al. TGFbeta2 in corneal morphogenesis during mouse embryonic development. Dev Biol. 2001;240:419-432.
15. Hahn P, Lindsten T, Tolentino M, Thompson CB, Bennett J, Dunaief JL. Persistent fetal ocular vasculature in mice deficient in bax and bak. Arch Ophthalmol 2005;123:797-802.
16. Li Y, Turck CM, Teumer JK, Stavnezer E. Unique sequence, ski, in Sloan-Kettering avian retroviruses with properties of a new cell-derived oncogene. J Virol 1986;57:1065-1072.
17. Stavnezer E, Gerhard DS, Binari RC, Balazs I. Generation of transforming viruses in cultures of chicken fibroblasts infected with an avian leukosis virus. J Virol 1981;39:920-934.
18. Sleeman JP, Laskey RA. Xenopus c-ski contains a novel coiled-coil protein domain, and is maternally expressed during development. Oncogene. 1993;8:67-77.
19. Kaufman CD, Martinez-Rodriguez G, Hackett PB. Ectopic expression of c-ski disrupts gastrulation and neural patterning in zebrafish. Mech Dev. 2000;95:147-162.
20. Namciu S, Lieberman MA, Stavnezer E. Induction of the c-ski proto-oncogene by phorbol ester correlates with induction of megakaryocyte differentiation. Oncogene 1994;9:1407-1416.
21. Nomura N, Sasamoto S, Ishii S, Date T, Matsui M, Ishizaki R. Isolation of human cDNA clones of ski and the ski-related gene, sno. Nucleic Acids Res. 1989;17:5489-5500.
22. Lyons GE, Micales BK, Herr MJ, et al. Protooncogene c-ski is expressed in both proliferating and postmitotic neuronal populations. Dev Dyn. 1994;201:354-365.
23. Xu W, Angelis K, Danielpour D, et al. Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factor. Proc Natl Acad Sci USA. 2000;97:5924-5929.
24. Akiyoshi S, Inoue H, Hanai J, et al. c-Ski acts as a transcriptional Co-repressor in transforming growth factor-beta signaling through interaction with smads. J Biol Chem. 1999;274:35269-35277.
25. Luo K, Stroschein SL, Wang W, et al. The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev. 1999;13:2196-2206.
26. Sun Y, Liu X, Eaton EN, Lane WS, Lodish HF, Weinberg RA. Interaction of the Ski oncoprotein with SmacB regulates TGF-beta signaling. Mol Cell. 1999;4:499-509.
27. Wang W, Mariani FV, Harland RM, Luo K. Ski represses bone morphogenic protein signaling in Xenopus and mammalian cells. Proc Natl Acad Sci USA 2000;97:14394-14399.
28. Dahl R, Kieslinger M, Beug H, Hayman MJ. Transformation of hematopoietic cells by the Ski oncoprotein involves repression of retinoic acid receptor signaling. Proc Natl Acad Sci USA. 1998;95:11187-11192.
29. Wilkinson DS, Ogden SK, Stratton SA, et al. A direct intersection between p53 and transforming growth factor beta pathways targets chromatin modification and transcription repression of the alpha-fetoprotein gene. Mol Cell Biol. 2005;25:1200-1212.
30. Berk M, Desai SY, Heyman HC, Colmenares C. Mice lacking the ski proto-oncogene have defects in neurulation, craniofacial, patterning, and skeletal muscle development. Genes Dev. 1997;11:2029-2039.
31. -/- mice. Nat Genet. 2002;30:106-109.
32. Artwohl J, Brown P, Corning B, Stein S, ACLAM Task Force. Report of the ACLAM task force on rodent euthanasia. J Am Assoc Lab Anim Sci. 2006;45:98-105.
33. Klaunberg BA, O'Malley J, Clark T, Davis JA. Euthanasia of mouse fetuses and neonates. Contemp Top Lab Anim Sci. 2004;43:29-34.
34. Azuma N, Yamaguchi Y, Handa H, et al. Mutations of the PAX6 gene detected in patients with a variety of optic-nerve malformations. Am J Hum Genet. 2003;72:1565-1570.
35. Hanson IM, Fletcher JM, Jordan T, et al. Mutations at the PAX6 locus are found in heterogeneous anterior segment malformations including Peters' anomaly. Nat Genet. 1994;6:168-173.
36. Vinores SA, Derevjanik NL, Mahlow J, et al. Class-III beta-tubulin in human retinal pigment epithelial cells in culture and in epiretinal membranes. Exp Eye Res. 1995;60:385-400.
37. Atanasoski S, Notterpek L, Lee HY, et al. The protooncogene Ski controls Schwann cell proliferation and myelination. Neuron. 2004;43:499-511.
38. Saint-Geniez M, D'Amore PA. Development and pathology of the hyaloid, choroidal and retinal vasculature. Int J Dev Biol. 2004;48:1045-1058.
39. Pei YF, Rhodin JA. The prenatal development of the mouse eye. Anat Rec. 1970;168:105-125.
40. Mitchell CA, Risau W, Drexler HC. Regression of vessels in the tunica vasculosa lentis is initiated by coordinated endothelial apoptosis: a role for vascular endothelial growth factor as a survival factor for endothelium. Dev Dyn. 1998;213:322-333.
41. Nomura T, Khan MM, Kaul SC, et al. Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor. Genes Dev. 1999;13:412-423.
42. Yamaguchi TP, Dumont DJ, Conlon RA, Breitman ML, Rossant J. flk-1, an fit-related receptor tyrosine kinase is an early marker for endothelial cell precursors. Development. 1993;118:489-498.
43. Millauer B, Wizigmann-Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 1993;72:835-846.
44. Yang K, Cepko CL. Flk-1, a receptor for vascular endothelial growth factor (VEGF), is expressed by retinal progenitor cells. J Neurosci. 1996;16:6089-6099.
45. Hirashima M, Ogawa M, Nishikawa S, et al. A chemically defined culture of VEGFR2+ cells derived from embryonic stem cells reveals the role of VEGFR1 in tuning the threshold for VEGF in developing endothelial cells. Blood. 2003;101:226l-2267.
46. Bohnsack BL, Hirschi KK. Red light, green light: signals that control endothelial cell proliferation during embryonic vascular development. Cell Cycle. 2004;3:1506-1511.
47. Traboulsi EI, Maumenee IH. Peters' anomaly and associated congenital malformations. Arch Ophthalmol. 1992;110:1739-1742.
48. Nishina S, Kohsaka S, Yamaguchi Y, et al. PAX6 expression in the developing human eye. Br J Ophthalmol. 1999;83:723-727.
49. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. A subset of p53-deficient embryos exhibit exencephaly. Nat Genet. 1995;10:175-180.
50. Thornton JD, Silva RL, Martin AC, Skapek SX. The Arf tumor suppressor regulates platelet-derived growth factor receptor beta signaling: a new view through the eyes of Arf (-/-) Mice. Cell Cycle. 2005;4:1316-1319.
51. Chang B, Smith RS, Peters M, et al. Haploinsufficient Bmp4 ocular phenotypes include anterior segment dysgenesis with elevated intraocular pressure. BMC Genet 2001;2:18.
52. Shapira SK, McCaskill C, Northrup H, et al. Chromosome 1p36 deletions: the clinical phenotype and molecular characterization of a common newly delineated syndrome. Am J Hum Genet. 1997;61:642-650.
53. Slavotinek A, Shaffer LG, Shapira SK. Monosomy 1p36. J Med Genet. 1999;36:657-663.